New imaging registry aims to sharpen cancer treatment precision
NCT ID NCT07636148
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner called spectral angio-CT captures extra imaging details. The goal is to see how this extra information relates to treatment success and could improve future planning and guidance. No experimental treatments are given, and patients receive standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors better plan and predict outcomes for minimally invasive cancer treatments using advanced imaging.
What could go wrong
This is an observational registry, not a treatment trial. It collects data only and does not test a new therapy, so direct patient benefits are not expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Assistance Publique Hopitaux de Paris - Hôpital Henri Mondor
Créteil, Île-de-France Region, 94000, France
Contact Email: •••••@•••••
Contact
-
Hospices Civils de Lyon - Hôpital Édouard Herriot
Lyon, Auvergne-Rhône-Alpes, 69002, France
Contact Email: •••••@•••••
Contact
-
Leiden University Medical Center
Leiden, South Holland, 2333 ZA, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact